Elsevier

European Journal of Radiology

Volume 84, Issue 12, December 2015, Pages 2633-2639
European Journal of Radiology

Prognostic value of pretreatment FDG PET in pediatric neuroblastoma

https://doi.org/10.1016/j.ejrad.2015.09.027Get rights and content

Abstract

Purpose

This study aimed to evaluate the prognostic value of pretreatment 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) in pediatric neuroblastoma patients.

Methods

The study included 50 pediatric neuroblastoma patients who underwent diagnostic work-up FDG PET before any treatment. The maximum standardized uptake value (SUVmax) of the primary tumor lesion (Pmax), the SUVmax of all the tumor lesions, including the primary tumor lesion and metastatic lesions (Tmax), and the uptake ratio of Tmax to mean SUV of normal liver tissue (Tmax/Lmean) were calculated and tested as prognostic factors.

Results

Of the 50 patients, 15 (30.0%) experienced disease progression and 21 (42.0%) died during the follow-up period. On univariate analysis, the histopathology, tumor stage, bone marrow involvement, serum levels of lactate dehydrogenase (LDH), neuron-specific enolase, and ferritin, primary tumor size, Pmax, Tmax, and Tmax/Lmean were significant prognostic factors for disease progression-free survival (PFS), whereas the tumor stage, serum level of LDH, Tmax, and Tmax/Lmean were determined to be significant for predicting overall survival (OS). On multivariate analysis, the histopathology and serum level of LDH were independent prognostic factors for PFS, and only the Tmax/Lmean was an independent prognostic factor for OS. The 2-year PFS and OS rates were over 80.0% in patients with low FDG uptake, meanwhile, patients with high FDG uptake showed the 2-year PFS of less than 30.0% and OS of less than 55.0%.

Conclusion

FDG PET was an independent prognostic factor for OS in neuroblastoma patients. FDG PET can provide effective information on the prognosis for neuroblastoma patients.

Introduction

Neuroblastoma is the most common extracranial pediatric malignancy and accounts for 8% of malignancies of children [1], [2]. At the time of diagnosis, approximately 70% of patients have distant metastasis, and the most common sites of metastasis are bone and bone marrow [3]. Although the 5-year event-free survival rate in patients with localized stage I disease is as high as 99%, the 5-year overall survival rate in neuroblastoma is 69%, and patients with distant metastasis have a 5-year event-free survival rate of less than 50% [4], [5], [6]. Hence, it is important to verify prognostic factors, which can be used to identify patients who are likely to fail treatment and have a worse prognosis. Several clinicohistopathological factors, including tumor stage, involvement of bone marrow, age at diagnosis, molecular pathologies, such as MYCN oncogene amplification, serum lactate dehydrogenase (LDH), neuron-specific enolase (NSE), and ferritin levels, and extent of radioiodine-labeled metaiodobenzylguanidine (MIBG) uptake, are known to be correlated with prognosis [5], [7], [8], [9], [10], [11].

18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) is a widely used imaging tool for many types of malignancies and metastasis, and FDG uptake by various types of malignant lesions has been shown to be a prognostic factor for predicting clinical outcomes [12], [13], [14], [15]. However, although the use of FDG PET in pediatric malignancies continues to evolve [16], few studies have evaluated the clinical role of FDG PET in pediatric neuroblastoma. Most of previous studies mainly focused on diagnostic performance of FDG PET and showed high accuracy to detect neuroblastoma lesion, even better than radioiodine-labeled MIBG scan in a selected population [16], [17], [18]. Meanwhile, only a single published study evaluated the prognostic significance of FDG PET in pediatric neuroblastoma [19].

In the present study, we aimed to evaluate the prognostic value of pretreatment FDG PET in pediatric patients with neuroblastoma and to compare its predictive value with those of other conventional prognostic factors.

Section snippets

Patients

The study has been approved by the institutional review board, and the need for written informed consent was waived. The electric medical records of 167 pediatric patients, who underwent diagnostic work-up for neuroblastoma in our medical center between 2003 and 2011, were retrospectively reviewed. Among them, a total of 50 patients with neuroblastoma, who underwent FDG PET as part of the diagnostic work-up before any treatment, were enrolled in the present study (Table 1). Patients, who had

Patient characteristics

Among the enrolled 50 patients, 15 patients (30.0%) experienced disease progression and 21 patients (42.0%) died during the follow-up period. The 2-year PFS and OS rates were 62.1% and 64.5%, respectively. Of the 50 patients, one patient showed disseminated hepatic metastases and Lmean could not be measured; therefore, the values of Tmax/Lmean were calculated in the remaining 49 patients. Of these 49 patients, two patients showed Pmax values which were less than the Lmean, and one patient

Discussion

Radioiodine-labeled MIBG scintigraphy has been used as the nuclear imaging modality of choice for pediatric neuroblastoma, but, recently, several studies have evaluated the diagnostic performance of FDG PET. Previous studies have demonstrated that radioiodine-labeled MIBG scintigraphy is superior to FDG PET in assessing the extent of neuroblastoma, especially metastatic lesions in the bone and bone marrow, mainly due to physiological accumulation of FDG in the bone marrow [16], [19], [20]. They

Conclusions

The present study demonstrated that FDG uptake measured on pretreatment FDG PET is an independent prognostic factor for predicting OS in patients with neuroblastoma. Patients with low FDG uptake have significantly better prognoses than patients with high FDG uptake. In addition, FDG PET remained a significant prognostic factor in a subgroup of patients with stage IV disease. FDG PET can effectively provide information on prognosis in neuroblastoma patients.

Conflicts of interest

None.

Acknowledgements

This study was supported by the National Research Foundation of Korea Grant funded by the Korean Government (Nos. 2012027176, NRF-2012R1A1A2041563) and National R&D Program for Cancer Control, Ministry of Health and Welfare (1320210).

References (25)

  • C. Spix et al.

    Survival of children with neuroblastoma. Time trends and regional differences in Europe, 1978–1992

    Eur. J. Cancer

    (2001)
  • G. Gatta et al.

    Childhood cancer survival in Europe 1999–2007: results of EUROCARE-5–a population-based study

    Lancet Oncol.

    (2014)
  • K. Kaira et al.

    Biological significance of 18F-FDG uptake on PET in patients with non-small-cell lung cancer

    Lung Cancer

    (2014)
  • G.M. Haase et al.

    Current aspects of biology, risk assessment, and treatment of neuroblastoma

    Semin. Surg. Oncol.

    (1999)
  • S.G. DuBois et al.

    Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival

    J. Pediatr. Hematol. Oncol.

    (1999)
  • S.L. Cohn et al.

    The International Neuroblastoma Risk Group (INRG) classification system: an INRG task force report

    J. Clin. Oncol.

    (2009)
  • W. Balwierz et al.

    Treatment results of children with neuroblastoma: report of Polish pediatric solid tumor group

    Przegl. Lek.

    (2010)
  • G. Cangemi et al.

    Prognostic value of ferritin, neuron-specific enolase, lactate dehydrogenase, and urinary and plasmatic catecholamine metabolites in children with neuroblastoma

    Onco Targets Ther.

    (2012)
  • G.P. Tonini et al.

    MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children

    J. Clin. Oncol.

    (1997)
  • G.A. Yanik et al.

    Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the children's oncology group

    J. Nucl. Med.

    (2013)
  • H.W. Hann et al.

    Prognostic importance of serum ferritin in patients with stages III and IV neuroblastoma: the Childrens Cancer Study Group experience

    Cancer Res.

    (1985)
  • S. Massaron et al.

    Neuron-specific enolase evaluation in patients with neuroblastoma

    Tumour Biol.

    (1998)
  • Cited by (24)

    • Diagnostic Value of <sup>18</sup>F-FDG PET/CT-Based Radiomics Nomogram in Bone Marrow Involvement of Pediatric Neuroblastoma

      2023, Academic Radiology
      Citation Excerpt :

      In addition, as an invasive method, it is stressful for the patient, especially pediatric patients who may require general anesthesia or sedation (29,30). 18F-FDG PET/CT is widely used in the evaluation of pediatric neuroblastoma and metastasis (31). As whole-body imaging, it offers synergistic advantages in terms of high contrast, spatial resolution, precise local assessment of diffuse and focal infiltrates using anatomical features, and the possibility of quantitative data interpretation (32,33).

    • Imaging in malignant adrenal cancers

      2022, Nuclear Medicine and Molecular Imaging: Volume 1-4
    • Roles of PET/Computed Tomography in the Evaluation of Neuroblastoma

      2020, PET Clinics
      Citation Excerpt :

      Based on 20 patients with MIBG-avid disease, Kang and colleagues59 reported that the progression-free survival of the patients with neuroblastoma was negatively related to the primary tumor’s maximum uptake value and tumor-to-background ratio on pretherapy 18F FDG-PET/CT images. Lee and colleagues60 analyzed 50 patients with pretherapy 18F FDG-PET/CT and found that 2-year progression-free survival and overall survival were more than 80.0% in patients with low 18F FDG uptake, but the patients with high FDG uptake had 2-year progression-free survival and overall survival progression-free survival of less than 30.0% and 55.0%, respectively. In addition, higher metabolic tumor volume, total lesion glycolysis, and abnormal activity in the bone marrow on FDG-PET/CT study are also regarded as poor prognostic factors.61

    • Energy metabolism and metabolic targeting of neuroblastoma

      2019, Neuroblastoma: Molecular Mechanisms and Therapeutic Interventions
    • Neuroblastoma: MIBG Imaging and New Tracers

      2017, Seminars in Nuclear Medicine
      Citation Excerpt :

      In addition they showed that a pattern of increased 18F-FDG uptake, exceeding the tumor avidity for 123I-MIBG, corresponded to more aggressive disease and worse outcome.62 Similar conclusions on a more selected (ie, drug naïve patients) and greater population of NB patients, have been recently reported by Lee et al.76 They showed that the FDG uptake expressed by SUVmax of the primary tumor lesion and metastatic lesions normalized for mean SUV of normal liver tissue was, in a multivariate analysis considering all the principal prognostic factors, the only one parameter significantly associated to overall survival.76 Liu et al77 recently observed an association between high 18F-FDG uptake of NB primary tumor and the most unfavorable genomic types such as MYCN amplification or segmental chromosomal alteration or both.

    • Specialty Imaging: PET

      2017, Specialty Imaging: PET
    View all citing articles on Scopus
    View full text